Immunotherapy drugs before surgery for vulvar cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether combining two immunotherapy drugs—nivolumab (given by IV) and imiquimod (a cream)—is safe and works in people with vulvar cancer that is hard to treat. The goal is to shrink the tumor before surgery, making it easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have vulvar cancer that can be removed with surgery.
- Your tumor(s) must be either large (more than 4 cm) or there are multiple spots on the vulva, or surgery would cause significant problems.
- You must have a tumor sample (biopsy) that can be reviewed by the study team.
- You must be well enough to carry out daily activities (performance status 0-2), and your blood counts and kidney/liver function must be within acceptable levels.
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study and for 5 months after the last dose.
- You cannot have had prior immunotherapy (like nivolumab), active autoimmune disease, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with early-stage vulvar cancer that can be surgically removed. It looks at the cancer's HPV and p53 status to decide how much tissue to remove, aiming to reduce side effects while keeping the cancer away.
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
This trial tests giving chemotherapy (carboplatin and paclitaxel) before surgery for certain cases of squamous cell vulvar cancer. It may help shrink the tumor and make surgery more effective.
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
Hear when a new Vulvar Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.